Patents by Inventor Tamer Coskun

Tamer Coskun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230408932
    Abstract: Embodiments described herein relate to a system, methods, and non-transitory computer-readable mediums that accurately align subsequent patterned layers in a photoresist utilizing a deep learning model and utilizing device patterns to replace alignment marks in lithography processes. The deep learning model is trained to recognize unique device patterns called alignment patterns in the FOV of the camera. Cameras in the lithography system capture images of the alignment patterns. The deep learning model finds the alignment patterns in the field of view of the cameras. An ideal image generated from a design file is matched with the camera with respect to the center of the field of view of the camera. A shift model and a rotation model are output from the deep learning model to create an alignment model. The alignment model is applied to the currently printing layer.
    Type: Application
    Filed: November 30, 2021
    Publication date: December 21, 2023
    Inventors: Tamer COSKUN, Yen-Shuo LIN, Aidyn KEMELDINOV
  • Patent number: 11834486
    Abstract: Incretin analogs are provided that have activity at each of the GIP, GLP-1 and glucagon receptors. The incretin analogs have structural features resulting in balanced activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases such as diabetes mellitus, dyslipidemia, fatty liver disease, metabolic syndrome, non-alcoholic steatohepatitis and obesity.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: December 5, 2023
    Assignee: Eli Lilly and Company
    Inventors: Jorge Alsina-Fernandez, Tamer Coskun, Lili Guo, Hongchang Qu
  • Publication number: 20230296987
    Abstract: Methods and systems for predictively determining tool drift in a digital lithography tool for early warning, and/or adjusting the tool in-situ to mitigate the effects of drift. Drift is measured during manufacturing by measuring alignment marks from eye-to-eye a bridge-to-bridge, among other methods. Measured drift is decomposed into three components: trend—trending drift over time, increment—rate of change of drift over time, and remaining—the difference between the drift, the trend, and the increment. Each component is provided to a machine learning engine, that predicts the next measurement of each component. Predicted measurements may be provided to the tool for use as adjustment parameters to modify how an eye module shoots a pattern onto a substrate, and/or as an early warning when predicted parameters are outside of a desired processing parameter window.
    Type: Application
    Filed: August 6, 2021
    Publication date: September 21, 2023
    Inventors: YenShuo LIN, Tamer COSKUN
  • Publication number: 20230293638
    Abstract: The present invention provides methods of treating type 2 diabetes (T2D) using a novel dosing regimen of a GIP:GLP-1 Peptide having a GIP:GLP-1 receptor agonist potency ratio that is about 2.5:1 to about 10:1 GIP to GLP-1. Furthermore, the present invention provides methods of treating T2D using a novel dosing regimen of a GIP:GLP-1 Peptide having a GIP:GLP-1 receptor agonist potency ratio that is about 2.5:1 to about 5:1 GIP to GLP-1. Also, the present invention provides methods of inducing T2D remission using a novel dosing regimen of a GIP:GLP-1 Peptide. The present invention also provides methods of treating obesity using a novel dosing regimen of a GIP:GLP-1 Peptide.
    Type: Application
    Filed: July 22, 2019
    Publication date: September 21, 2023
    Inventors: Jorge ALSINA-FERNANDEZ, Over CABRERA, Tamer COSKUN
  • Publication number: 20230203121
    Abstract: Incretin analogs are provided that have activity at each of the GIP, GLP-1 and glucagon receptors. The incretin analogs have structural features resulting in balanced activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases such as diabetes mellitus, dyslipidemia, fatty liver disease, metabolic syndrome, non-alcoholic steatohepatitis and obesity.
    Type: Application
    Filed: November 21, 2022
    Publication date: June 29, 2023
    Inventors: Jorge Alsina-Fernandez, Tamer Coskun, Lili Guo, Hongchang Qu
  • Publication number: 20230190944
    Abstract: The present disclosure related to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity, and/or dyslipidemia. The disclosure relates to compounds that agonize both the calcitonin and amylin receptors and can lower food intake, body weight, glucose and/or triglycerides, so can be used to treat diabetes, obesity and/or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.
    Type: Application
    Filed: October 28, 2022
    Publication date: June 22, 2023
    Inventors: Tamer COSKUN, Hongchang QU
  • Publication number: 20230190945
    Abstract: The present disclosure related to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity, and/or dyslipidemia. The disclosure relates to compounds that agonize both the calcitonin and amylin receptors and can lower food intake, body weight, glucose and/or triglycerides, so can be used to treat diabetes, obesity and/or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.
    Type: Application
    Filed: October 28, 2022
    Publication date: June 22, 2023
    Inventors: Tamer COSKUN, Hongchang QU
  • Publication number: 20230102339
    Abstract: Incretin analogs are provided that have activity at each of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptors. The incretin analogs have structural features resulting in balanced activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases such as type 2 diabetes mellitus, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and obesity.
    Type: Application
    Filed: December 11, 2020
    Publication date: March 30, 2023
    Inventors: Milata Mary Abraham, Jorge Alsina-Fernandez, Tamer Coskun, Hongchang Qu, James Lincoln Wallis
  • Publication number: 20230040198
    Abstract: Systems and methods disclosed are generally related to masklessly developing connections between a chip-group and a design connection point on a substrate. In placement of the chip-group on the substrate, according to certain embodiments the chip-group may be dispositioned relative to an expected position per a substrate layout design, causing a connection misalignment with the design connection point. According to certain embodiments, a machine learning (ML) model is trained on historical and simulated pixel models of chip-group connections and design connection points. Upon determining the chip-group misalignment by a metrology measurement, the trained ML model determines a pixel model to connect the misaligned chip-group, and causes the pixel model to be exposed to a substrate with a digital lithography tool, thereby connecting the dispositioned chip-group to the design connection point.
    Type: Application
    Filed: August 6, 2021
    Publication date: February 9, 2023
    Inventors: Tamer COSKUN, Aidyn KEMELDINOV, Chung-Shin KANG, Uwe HOLLERBACH, Thomas L. LAIDIG
  • Patent number: 11542313
    Abstract: Incretin analogs are provided that have activity at each of the GIP, GLP-1 and glucagon receptors. The incretin analogs have structural features resulting in balanced activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases such as diabetes mellitus, dyslipidemia, fatty liver disease, metabolic syndrome, non-alcoholic steatohepatitis and obesity.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: January 3, 2023
    Assignee: Eli Lilly and Company
    Inventors: Jorge Alsina-Fernandez, Tamer Coskun, Lili Guo, Hongchang Qu
  • Patent number: 11541123
    Abstract: The present disclosure related to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity, and/or dyslipidemia. The disclosure relates to compounds that agonize both the calcitonin and amylin receptors and can lower food intake, body weight, glucose and/or triglycerides, so can be used to treat diabetes, obesity and/or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: January 3, 2023
    Assignee: Eli Lilly and Company
    Inventors: Tamer Coskun, Hongchang Qu
  • Publication number: 20220382171
    Abstract: Embodiments of the present disclosure relate to a system, a software application, and a method of a lithography process to update one or more of a mask pattern, maskless lithography device parameters, lithography process parameters utilizing a file readable by each of the components of a lithography environment. The file readable by each of the components of a lithography environment stores and shares textual data and facilitates communication between of the components of a lithography environment such that the mask pattern corresponds to a pattern to be written is updated, the maskless lithography device of the lithography environment is calibrated, and process parameters of the lithography process are corrected for accurate writing of the mask pattern on successive substrates.
    Type: Application
    Filed: October 8, 2019
    Publication date: December 1, 2022
    Inventors: Tamer COSKUN, Jang Fung CHEN, Douglas Joseph VAN DEN BROEKE
  • Publication number: 20220193245
    Abstract: The present disclosure related to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity, and/or dyslipidemia. The disclosure relates to compounds that agonize both the calcitonin and amylin receptors and can lower food intake, body weight, glucose and/or triglycerides, so can be used to treat diabetes, obesity and/or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.
    Type: Application
    Filed: December 17, 2021
    Publication date: June 23, 2022
    Inventors: Tamer COSKUN, Hongchang QU
  • Publication number: 20220125885
    Abstract: Glucagon analog agonist compounds are provided herein that have improved solubility, as well as improved chemical and physical stabilities, when compared to native, human glucagon. Also provided are pharmaceutical compositions including such glucagon analog agonist compounds, as well as methods of using the same for treating hypoglycemia, especially severe hypoglycemia.
    Type: Application
    Filed: January 29, 2020
    Publication date: April 28, 2022
    Inventors: Jorge Alsina-Fernandez, Tamer Coskun, Andrea Renee Geiser
  • Publication number: 20220048967
    Abstract: The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. Compounds may be useful in the treatment of type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.
    Type: Application
    Filed: July 2, 2021
    Publication date: February 17, 2022
    Inventors: Milata Mary ABRAHAM, Jorge ALSINA-FERNANDEZ, Robert Andrew BROWN, Over CABRERA, Tamer COSKUN, Robert Chadwick CUMMINS, Mohamed ElSayed Hamed ELSAYED, Hongchang QU, James Lincoln WALLIS, Kyle Wynn SLOOP, Francis Stafford WILLARD, Thi Thanh Huyen TRAN, Aktham ABURUB, Phenil Jayantilal PATEL, Amita DATTA-MANNAN, Xianyin LAI
  • Patent number: 11084861
    Abstract: The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. Compounds may be useful in the treatment of type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: August 10, 2021
    Assignee: Eli Lilly and Company
    Inventors: Milata Mary Abraham, Jorge Alsina-Fernandez, Robert Andrew Brown, Over Cabrera, Tamer Coskun, Robert Chadwick Cummins, Mohamed ElSayed Hamed Elsayed, Hongchang Qu, James Lincoln Wallis, Amita Datta-Mannan, Xianyin Lai
  • Publication number: 20210221865
    Abstract: Incretin analogs are provided that have activity at each of the GIP, GLP-1 and glucagon receptors. The incretin analogs have structural features resulting in balanced activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases such as diabetes mellitus, dyslipidemia, fatty liver disease, metabolic syndrome, non-alcoholic steato-hepatitis and obesity.
    Type: Application
    Filed: December 14, 2018
    Publication date: July 22, 2021
    Inventors: Jorge Alsina-Fernandez, Tamer Coskun, Lili Guo, Hongchang Qu
  • Publication number: 20210216019
    Abstract: The present disclosure generally relates to photolithography systems, and methods for correcting positional errors in photolithography systems. When a photolithography system is first started, the system enters a stabilization period. During the stabilization period, positional readings and data, such as temperature, pressure, and humidity data, are collected as the system prints or exposes a substrate. A model is created based on the collected data and the positional readings. The model is then used to estimate errors in subsequent stabilization periods, and the estimated errors are dynamically corrected during the subsequent stabilization periods.
    Type: Application
    Filed: March 30, 2021
    Publication date: July 15, 2021
    Inventors: Tamer COSKUN, Muhammet POYRAZ, Qin ZHONG, Pacha MONGKOLWONGROJN
  • Patent number: 10996572
    Abstract: The present disclosure generally relates to photolithography systems, and methods for correcting positional errors in photolithography systems. When a photolithography system is first started, the system enters a stabilization period. During the stabilization period, positional readings and data, such as temperature, pressure, and humidity data, are collected as the system prints or exposes a substrate. A model is created based on the collected data and the positional readings. The model is then used to estimate errors in subsequent stabilization periods, and the estimated errors are dynamically corrected during the subsequent stabilization periods.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: May 4, 2021
    Assignee: Applied Materials, Inc.
    Inventors: Tamer Coskun, Muhammet Poyraz, Qin Zhong, Pacha Mongkolwongrojn
  • Patent number: 10935892
    Abstract: Methods and systems are provided that, in some embodiments, print and process a layer. The layer can be on a wafer or on an application panel. Thereafter, locations of the features that were actually printed and processed are measured. Based upon differences between the measured differences and designed locations for those features at least one distortion model is created. Each distortion model is inverted to create a corresponding correction model. When there are multiple sections, a distortion model and a correction model can be created for each section. Multiple correction models can be combined to create a global correction model.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: March 2, 2021
    Assignee: APPLIED MATERIALS, INC.
    Inventors: Tamer Coskun, Thomas L. Laidig, Jang Fung Chen